Blueprint Medicines Corp Stock Price, News & Analysis

Blueprint Medicines Corporation (Nasdaq: BPMC) announced the grant of stock options and restricted stock units (RSUs) to fourteen new employees effective November 1, 2022. A total of 15,656 stock options and 7,824 RSUs were awarded under the 2020 Inducement Plan, designed for individuals not previously associated with the company. The stock options have an exercise price of $48.24, equal to the closing stock price on the grant date. Vesting schedules include a 25% vesting after one year, followed by monthly or annual vesting, contingent on continued employment.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced the acceptance of abstracts for presentation at the 2022 American Society of Hematology (ASH) Annual Meeting, showcasing the long-term outcomes of AYVAKIT® (avapritinib) in advanced systemic mastocytosis (SM). Key highlights include an oral presentation on the PATHFINDER trial and a poster on the EXPLORER trial. A late-breaking abstract from the PIONEER trial on non-advanced SM will also be presented. The meeting is set for December 10-11, 2022, at the Ernest N. Morial Convention Center.

Blueprint Medicines (BPMC) announced key updates during its Investor Day on November 1, 2022, reiterating total revenue guidance of $180-$200 million for 2022. The company plans to submit a supplemental New Drug Application for AYVAKIT® for non-advanced systemic mastocytosis and aims for a U.S. launch in mid-2023. The recent SYMPHONY trial data supports the clinical activity of BLU-945 in EGFR-mutant lung cancer. Blueprint's five-year strategy aims for four or more marketed products by 2027, enhancing its commercial footprint.

Blueprint Medicines Corporation (Nasdaq: BPMC) will host an Investor Day on November 1, 2022, at 8:30 a.m. ET in New York City. The event aims to showcase the company's plans for enhancing precision medicine accessibility, featuring presentations from management and a panel discussion with experts in mastocytosis and immunology. Additionally, Blueprint Medicines will report its third quarter 2022 financial results on the same day, with a live webcast available on their website.

Blueprint Medicines Corporation (Nasdaq: BPMC) announced on October 6, 2022, that its Compensation Committee granted non-qualified stock options for 11,381 shares and 5,688 restricted stock units (RSUs) to eight new employees, effective October 1, 2022. This is part of the 2020 Inducement Plan, aimed at attracting new talent. The options have an exercise price of $65.89 per share, equal to the closing price on September 30, 2022, and will vest over a four-year period. The RSUs will also vest over four years, contingent on continued employment.

Blueprint Medicines Corporation (Nasdaq: BPMC) announced on September 6, 2022, that its Compensation Committee granted stock options for 18,170 shares and 9,083 restricted stock units (RSUs) to thirteen new employees as part of the 2020 Inducement Plan. The options have an exercise price of $73.83 per share, equal to the closing price on the grant date of September 1, 2022. Vesting for options occurs over four years, while RSUs vest 25% annually, contingent on continued employment.

Blueprint Medicines Corporation (NASDAQ: BPMC) announced the publication of research indicating significant symptom burden in systemic mastocytosis (SM) patients. Published in the journal CANCER, the study highlights severe symptoms including pain, frequent emergency visits, and a substantial impact on quality of life. Results showed that 66% of patients faced work interference due to symptoms, with over 50% requiring multiple medications. The research emphasizes the urgent need for improved therapies to enhance the quality of life for those affected by SM.

Blueprint Medicines Corporation (NASDAQ: BPMC) reported positive results from the registrational Part 2 of the PIONEER clinical trial for AYVAKIT (avapritinib), showing significant improvements in patients with non-advanced systemic mastocytosis. Highlighted metrics include a mean change in total symptom score reduction of 15.6 points at 24 weeks (p=0.003) and over 50% of patients achieving a reduction in serum tryptase. The company plans to file a supplemental new drug application with the FDA in Q4 2022, potentially paving the way for AYVAKIT to be a groundbreaking treatment for this condition.

Guardant Health and Blueprint Medicines presented new data at the IASLC 2022 World Conference on Lung Cancer, revealing that the EGFR C797X mutation is a prevalent resistance mechanism to osimertinib for advanced non-small cell lung cancer (NSCLC) patients. The cumulative incidence of this mutation was found to be 12.5% after first-line treatment. The collaboration utilized the GuardantINFORM platform to analyze data from over 2,000 patients, emphasizing the need for next-generation EGFR inhibitors to combat C797X-driven resistance in NSCLC.